Tirz Rx

Unopened tirzepatide needs a fridge (36-46°F). Once in use, most pens/vials tolerate room temp for 21-30 days. Here's the FDA-sourced breakdown by product.

Tirzepatide can curb appetite within days, but real weight loss and A1C drops build over 4 to 9 months. Here's the week-by-week timeline from trial data.

How to reconstitute compounded tirzepatide correctly: BAC water ratios, mixing technique, storage times, and the mistakes that ruin a vial. Step-by-step guide.

A practical checklist for verifying tirzepatide quality: COA review, USP <797> facts, FDA shortage status, and questions every compounding pharmacy should answer.

Tirz Rx is an information platform, not a drug. Only tirzepatide itself (Mounjaro, Zepbound) is FDA approved. Here's how to check what you're getting.

Tirzepatide safety by the numbers: GI side effects in 70%+ of trial patients, a boxed MTC warning, and what SURMOUNT and SURPASS actually found.

Is tirzepatide banned in sport? WADA doesn't list GLP-1/GIP drugs on the 2025 Prohibited List, but athletes should still know the gray areas. Here's the evidence.

Which labs matter before and during tirzepatide treatment, how often to recheck them, and what SURPASS and SURMOUNT trial data show about changes over time.

Rodent thyroid tumors vs SURPASS and SURMOUNT human data: what tirzepatide's animal studies actually showed, and why the FDA still approved it.

Before and after photos aren't data. Here's what SURMOUNT and SURPASS actually recorded on tirzepatide weight loss and A1C over 36 to 72 weeks.

What a tirzepatide COA should show, what third-party testing costs, and how to spot a fake report before you trust a vial.

SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks; SURPASS trials cut A1C by up to 2.4 points. Here's what the tirzepatide trial data actually says.

Compounding pharmacies require a prescription and licensed oversight; research suppliers sell unregulated peptides with no chain of custody. Here's the real difference.

A personal or family history of MTC or MEN2 is an absolute contraindication. Full breakdown of who should avoid tirzepatide, per FDA labeling and SURMOUNT/SURPASS data.

Zepbound list price is $1,059.87/month. Insurance, savings cards, and compounded routes change that math a lot. Here's the real breakdown.

There's no fixed tirzepatide cycle. SURMOUNT trials ran 36-72 weeks continuously. Here's what the data says about duration, titration, and stopping.

Tirzepatide starts at 2.5mg weekly and titrates to a 15mg max. Here's the full FDA schedule from SURMOUNT and SURPASS, with real numbers on timing and side effects.

A tirzepatide dosage calculator only converts mg to mL and units. See the real FDA titration schedule (2.5mg to 15mg) and how to check any calculator's math.

Full breakdown of tirzepatide drug interactions: oral meds slowed by delayed gastric emptying, insulin/sulfonylureas, warfarin, birth control pills, and more.

Tirzepatide's half life is about 5 days, per FDA labeling. See what that means for dosing intervals, missed doses, washout time, and drug clearance.

Tirzepatide is injected subcutaneously once weekly. Here's the full injection protocol: needle size, sites, angle, rotation, and what the SURMOUNT trials actually used.

SURPASS and SURMOUNT enrolled over 15,000 people. Here's what the tirzepatide human studies found on weight loss, A1c, and side effects, trial by trial.

Women lost 15-21% of body weight on tirzepatide in SURMOUNT trials. Here's what the data says on PCOS, fertility, menstrual cycles, pregnancy risk, and dosing.

Abdomen, thigh, or upper arm: the FDA label allows all three. Here's the injection site rotation schedule that actually cuts down on skin reactions.

Zepbound and Mounjaro are FDA-approved; compounded tirzepatide is legal in narrower cases. Here's the real regulatory picture, sourced from FDA and NCT trial data.

5-year SURMOUNT data on tirzepatide's long term side effects: GI symptoms, gallbladder risk, pancreatitis signal, and the MTC boxed warning explained.

Tirzepatide activates GLP-1 and GIP receptors together. Here's the receptor biology, trial data (SURMOUNT, SURPASS), and what it means for side effects and dosing.

Tirzepatide requires a prescription by federal law (FDCA Section 503). Here's what a legit prescriber checks, what disqualifies you, and how telehealth actually works.

FDA-approved tirzepatide has 99%+ purity by USP standard. Compounded versions vary. Here's what testing actually proves and how to check before you buy.

SURMOUNT and SURPASS trial data on tirzepatide: up to 22.5% weight loss and A1C drops of 2.1 points. See the real numbers, timelines, and risks.

Nausea hits 12-24% of tirzepatide users across dose levels; gallbladder disease and a rodent thyroid tumor warning are the bigger long-term concerns. Full breakdown.

Unopened tirzepatide stays cold (2-8°C) until the expiration date; in-use pens last 21-31 days at room temp. Here's what the labels actually say.

What happens on tirzepatide from week 1 to month 18, based on SURMOUNT and SURPASS trial data. Dosing, side effects, and weight loss by timepoint.

Mounjaro and Zepbound are the same FDA drug, tirzepatide, at different doses for different labels. Here's the real trial data, cost, and how compounded fits in.

Tirzepatide vs semaglutide (Ozempic): SURPASS/SURMOUNT vs STEP trial data, weight loss %, dosing, side effects, and cost compared head-to-head.

Tirzepatide has FDA approval and phase 3 data showing up to 20.9% weight loss. Retatrutide is still in trials, with phase 2 results near 24%. Full comparison.

Head-to-head trial data: tirzepatide averaged 15-21% weight loss vs semaglutide's 15%. Compare SURMOUNT, STEP, dosing, side effects, and cost.

Wegovy averaged 15.2% weight loss at 68 weeks; tirzepatide hit 20.9% at 72 weeks (SURMOUNT-1). Full head-to-head on dosing, cost, and side effects.

Tirz Rx connects patients with providers who can prescribe tirzepatide, fulfilled by licensed pharmacies. It does not compound, sell, or ship the drug itself.